Download PDF
Synlett 2021; 32(11): 1109-1116
DOI: 10.1055/a-1500-6863
letter

Synthesis of Dihydropyrrole Derivatives by Oxidative Functionalization of 2-Amino-4H-Chromenes Using Hypervalent Iodine Reagents

Divakar Reddy Indukuri
a   Division of Fluoro and Agro Chemicals, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500007, India
c   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India
,
Gal Reddy Potuganti
a   Division of Fluoro and Agro Chemicals, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500007, India
c   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India
,
Jagadeesh Babu Nanubolu
b   Centre for X-ray Crystallography, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500007, India
c   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India
,
Manjula Alla∗
a   Division of Fluoro and Agro Chemicals, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500007, India
c   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India
› Author AffiliationsI.D.R. thanks DST and P.G.R. thanks Council of Scientific and Industrial Research, India (CSIR) for a fellowship.
› Further Information
   Permissions and Reprints All articles of this category


Abstract

An efficient simple, metal-free, one-pot protocol for the synthesis of dihydropyrrole derivatives has been achieved via sequential addition of iodobenzenediacetate and secondary amine to 2-amino-4H- pyran derivatives. The one-pot protocol proceeds through tandem oxidative functionalization, rearrangement, and ring contraction to provide an entirely new strategy for the construction of the dihydropyrrole skeleton.

Key words

one pot - metal free - oxidative functionalization - rearrangement - ring contraction

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/a-1500-6863.
  • Supporting Information


Publication History

Received: 03 March 2021

Accepted after revision: 05 May 2021

Accepted Manuscript online:
05 May 2021

Article published online:
28 May 2021

© 2021. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References and Notes

  • 1 Peng H, Bryan J, Henson W, Zhdankin VV, Gandhi K, David S. J. Chem. Educ. 2019; 96: 2622
    Crossref
    • 2a Matousek V, Pietrasiak E, Schwenk R, Togni A. J. Org. Chem. 2013; 78: 6763
      CrossrefPubMed
    • 2b Dohi T, Kita Y. Chem. Commun. 2009; 2073
      PubMed
    • 3a Mekhman S, Yusubov VV, Zhdankin MS, Yusubov V, Zhdankin V. Resour.-Effic. Technol. 2015; 1: 49
    • 3b Sousa e Silva FC, Tireno AF, Wengryniuk SE. Molecules 2017; 22: 780
      CrossrefPubMed
  • 4 Koser GF. Aldrichimica Acta 2001; 34: 89
    CrossrefPubMed
    • 5a Zhang B.: Xiaoxian Li, Guob B, Du Y. Chem. Commun. 2020; 56: 14119
      CrossrefPubMed
    • 5b Loudon GM, Radhakrishna AS, Almond MR, Blodgett JK, Boutin RH. J. Org. Chem. 1984; 49: 4272
      Crossref
    • 5c Farid U, Malmedy F, Claveau R, Albers L. Angew. Chem. Int. Ed. 2013; 52: 7018
      CrossrefPubMed
    • 6a Fujita M, Mori K, Shimogaki M, Sugimura T. Org. Lett. 2012; 14: 1294
      CrossrefPubMed
    • 6b Mizar P, Laverny A, El-Sherbini M, Farid U, Brown M, Malmedy F, Wirth T. Chem. Eur. J. 2014; 20: 9910
      CrossrefPubMed
    • 7a Chi Y, Zhang WX, Xi Z. Org. Lett. 2014; 16: 6274
      CrossrefPubMed
    • 7b Xing L, Zhang Y, Bing L, Yunfei D. Org. Lett. 2019; 21: 1989
      CrossrefPubMed
    • 7c Hori M, Guo JD, Yanagi Yanagi, Nogi TK, Sasamori T, Yorimitsu H. Angew. Chem. Int. Ed. 2018; 57: 4663
      CrossrefPubMed
    • 8a Kong W, Feige P, de Haro T, Nevado C. Angew. Chem. Int. Ed. 2013; 52: 2529
      CrossrefPubMed
    • 8b Kong W, Feige P, de Haro T, Nevado C. Angew. Chem. Int. Ed. 2013; 52: 2469
      CrossrefPubMed
  • 9 Roben C, Souto JA, Escudero-Ad EC, Muciz K. Org. Lett. 2013; 15: 1008
    CrossrefPubMed
    • 10a Zhong M, Liu S, Yang J, Meng X, Li Z. Org. Lett. 2012; 14: 3336
      CrossrefPubMed
    • 10b Yan J, Wang H, Yang Z, He Y. Synlett 2009; 2669
    • 10c Zhou ZS, He XH. Tetrahedron Lett. 2010; 51: 2480
      Crossref
    • 10d Fujita M, Yoshida Y, Miyata K, Wakisaka A, Sugimura T. Angew. Chem. Int. Ed. 2010; 49: 7222
      CrossrefPubMed
    • 10e Fujita M, Yoshida Y, Miyata K, Wakisaka A, Sugimura T. Angew. Chem. Int. Ed. 2010; 49: 7068
      CrossrefPubMed
    • 11a Indukuri DR, Potuganti GR, Alla M. Synlett 2019; 30: 1573
      Article in Thieme Connect
    • 11b Satkar Y, Ramadoss V, Nahide PD, Garciamedina E, Juarez-Orneals KA, Alonso-Castro AJ, Chavez-Rivera R, Jimenez-Halla JO, Solorio-Alvarado CR. RSC Adv. 2018; 8: 17806
      CrossrefPubMed
  • 12 Kamal R, Kumar V, Kumar R. Asian J. Org. Chem. 2016; 11: 1988
    CrossrefPubMed
  • 13 Liu W, Chen C, Zhang Q, Zhu Z. Beilstein J. Org. Chem. 2011; 7: 1436
    CrossrefPubMed
  • 14 Yoshimura A, Zhdankin VV. Chem. Rev. 2016; 116: 3328
    CrossrefPubMed
    • 15a Jacquemot G, Canesi S. J. Org. Chem. 2012; 77: 7588
      CrossrefPubMed
    • 15b Beaulieu MA, Gurard KC, Maertens G, Sabot C, Canesi S. J. Org. Chem. 2011; 76: 9460
      CrossrefPubMed
    • 15c Justik MW, Koser GF. Molecules 2005; 10: 217
      CrossrefPubMed
    • 15d Silva LF, Vasconcelos RS. Jr, Nogueira MA. Org. Lett. 2008; 10: 1017
      CrossrefPubMed
    • 15e Ahmad A, Silva LF. Jr. J. Org. Chem. 2016; 81: 2174
      CrossrefPubMed
    • 15f Liu L, Du L, Zhang-Negrerie D, Du Y, Zhao K. Org. Lett. 2014; 16: 5772
      CrossrefPubMed
    • 15g Purohit VC, Allwein SP, Bakale RP. Org. Lett. 2013; 15: 1650
      CrossrefPubMed
    • 16a Mandha SR, Alla M, Bommena VR, Nanubolu JB, Lingala SR, Yarasi S. J. Org. Chem. 2012; 77: 10648
      CrossrefPubMed
    • 16b Mandha SR, Alla M, Nanubolu JB. Org. Biomol. Chem. 2014; 12: 4412
      CrossrefPubMed
  • 17 Li X, Du Y, Liang Z, Li X, Pan Y, Zhao K. Org. Lett. 2009; 11: 2643
    CrossrefPubMed
  • 18 Mukherjee P, Das AR. J. Org. Chem. 2016; 81: 5513
    CrossrefPubMed
    • 19a Kale A, Medishetti N, Nanubolu JB, Atmakur K. Synth. Commun. 2020; 50: 3264
      Crossref
    • 19b Kale A, Chennapuram M, Bingi C, Nanubolu JB, Atmakur K. Org. Biomol. Chem. 2016; 14: 582
      CrossrefPubMed
  • 20 Bhattacharyya P, Pradhan k, Paul S, Das AR. Tetrahedron Lett. 2012; 53: 4687
    Crossref
  • 21 Mukherjee P, Das AR. RSC Adv. 2016; 6: 132
    Crossref
  • 22 Lin Z, Zhang X, You X, Gao Y. Tetrahedron 2012; 68: 6759
    CrossrefPubMed
    • 23a Rane R, Sahu N, Shah C, Karpoormath R. Curr. Top. Med. Chem. 2014; 14: 253
      PubMed
    • 23b Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath AK. Antimicrob. Agents Chemother. 2004; 48: 4349
      CrossrefPubMed
    • 23c Chauhan M, Kumar R. Med. Chem. Res. 2015; 24: 2259
      Crossref
    • 24a Young IS, Thornton PD, Thompson A. Nat. Prod. Rep. 2010; 27: 1801
      CrossrefPubMed
    • 24b Wood JM, Furkert DP, Brimble MA. Nat. Prod. Rep. 2019; 36: 289
      CrossrefPubMed
    • 24c Nguyen UT. T, Guo Z, Delon C, Wu Y, Deraeve C, Franzel B, Bon RS, Blankenfeldt W, Goody RS, Waldmann H, Wolters D, Alexandrov K. Nat. Chem. Biol. 2009; 5: 227
      CrossrefPubMed
    • 24d Petri GL, Span V, Spatola R, Holl R, Raimondi MV, Barraja P, Montalbano A. Eur. J. Med. Chem. 2020; 208: 112783
      CrossrefPubMed
  • 25 Bulumulla C, Gunawardhana R, Gamage PL, Miller JT, Kularatne RN, Biewer MC, Stefan MC. ACS Appl. Mater. Interfaces 2020; 12: 32209
    CrossrefPubMed
  • 26 Sharley DD. S, Williams JM. J. Chem. Commun. 2017; 53: 2020
    CrossrefPubMed
  • 27 General Procedure for the Preparation of Dihydropyrrole Derivatives A mixture of 2-amino-5-oxo-4-phenyl-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (1 mmol, 1 equiv) and IBD (1.1 mmol, 1.1 equiv) in anhydrous DCM (3 mL) was stirred for 60 min, then secondary amine derivatives were added. Stirring was continued at room temperature until the starting material was completely consumed (TLC monitoring). After completion, the reaction mixture was extracted with DCM (20 mL) and washed with water (10 mL). The combined organic layers were dried (anhydrous Na2SO4) and evaporated under reduced pressure to dryness. The crude product thus obtained was purified by column chromatography (60–120 mesh, and EtOAc–hexane, 30:70) to afford the pure product.
  • 28 Analytical Data
    3-(4-Chlorophenyl)-4-oxo-2-(piperidine-1-carbonyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5a)     Yield: 134 mg (70%); white solid; mp156–158 °C. 1H NMR (500 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 2 H), 7.25 (dd, J = 7.8, 5.4 Hz, 2 H), 5.53 (s, 1 H), 4.39 (s, 1 H), 3.58 (m, 4 H), 2.59 (q, J = 6.4 Hz, 2 H), 2.29–2.22 (m, 2 H), 2.11–2.03 (m, 2 H), 1.68–1.58 (m, 2 H), 1.30 (dt, J = 13.8, 7.0 Hz, 2 H), 0.88 (t, J = 7.1 Hz, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.38, 167.41, 163.51, 136.17, 134.48, 129.36, 115.88, 77.06, 67.33, 54.35, 47.59, 45.53, 36.44, 25.36, 25.13, 24.06, 23.70, 22.20. HRMS-ESI: m/z [M + H]+ calcd for C21H23O2N3Cl: 384.14869; found: 384.14733. 3-(4-Chlorophenyl)-2-[4-(4-fluorophenyl)piperazine-1-carbonyl]-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5b) Yield: 155 mg (65%); white solid; mp 212–214 °C. 1H NMR (500 MHz, CDCl3): δ = 7.39–7.36 (m, 2 H), 7.28–7.25 (m, 2 H), 7.02–6.97 (m, 2 H), 6.92–6.88 (m, 2 H), 5.47 (s, 1 H), 4.44 (s, 1 H), 4.07–3.62 (m, 4 H), 3.31–3.01 (m, 4 H), 2.61 (dd, J = 13.8, 6.7 Hz, 2 H), 2.29–2.24 (m, 2 H), 2.10–2.07 (m, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.40, 167.21, 163.92, 159.26, 156.80, 147.11, 135.86, 134.68, 129.40, 119.02, 115.99, 115.77, 67.28, 54.55, 50.40, 49.76, 46.59, 44.22, 36.43, 23.70, 22.20. HRMS-ESI: m/z [M + H]+ calcd for C26H25O2N4ClF: 479.16507; found: 479.16446. 3-(4-Chlorophenyl)-2-[4-(2-methoxyphenyl)piperazine-1-carbonyl]-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5c) Yield: 147 mg (60%); off-white solid; mp 204–206 °C. 1H NMR (500 MHz, CDCl3): δ = 7.32 (dd, J = 5.4, 3.5 Hz, 2 H), 7.29–7.27 (m, 1 H), 7.21 (dt, J = 6.8, 1.9 Hz, 1 H), 7.06 (m, 1 H), 6.95–6.89 (m, 3 H), 5.51 (s, 1 H), 4.44 (s, 1 H), 3.95 (s, 1 H), 3.90 (s, 3 H), 3.87–3.75 (m, 3 H), 3.22 (dd, J = 10.3, 5.9 Hz, 3 H), 3.07–2.99 (m, 1 H), 2.66–2.57 (m, 2 H), 2.31–2.26 (m, 2 H), 2.12–2.08 (m, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.36, 167.51, 163.83, 152.30, 139.97, 139.42, 135.02, 130.44, 129.02, 128.12, 126.37, 124.04, 121.16, 118.72, 115.76, 115.55, 111.46, 67.26, 55.55, 54.73, 50.24, 49.80, 46.98, 44.54, 36.44, 23.71, 22.18. HRMS-ESI: m/z [M + H]+ calcd for C27H28O3N4Cl: 491.18498; found: 491.18444. 3-(4-Chlorophenyl)-2-[4-(4-nitrophenyl)piperazine-1-carbonyl]-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5d) Yield: 189 mg (75%); yellow solid; mp 246–248 °C. 1H NMR (500 MHz, CDCl3): δ = 8.18–8.16 (m, 1 H), 7.35 (dd, J = 4.7, 1.9 Hz, 1 H), 7.31–7.28 (m, 1 H), 7.24–7.21 (m, 1 H), 6.91–6.87 (m, 2 H), 5.42 (s, 1 H), 4.42 (s, 1 H), 4.20–4.07 (m, 1 H), 3.93 (s, 1 H), 3.70 (dd, J = 68.9, 29.8 Hz, 4 H), 3.49–3.31 (m, 2 H), 2.70–2.57 (m, 2 H), 2.31–2.26 (m, 2 H), 2.14–2.07 (m, 2 H). 13C NMR (101 MHz, CDCl3 + DMSO): δ = 189.86, 167.29, 162.23, 153.13, 139.11, 137.40, 132.97, 129.03, 127.10, 126.91, 125.60, 124.51, 114.81, 112.00, 110.84, 66.83, 52.69, 44.93, 35.20, 22.22, 20.96. HRMS-ESI: m/z [M + H]+ calcd for C26H25O4N5Cl: 506.16003; found: 506.15896 3-(4-Chlorophenyl)-4-oxo-2-[4-(pyridin-2-yl)piperazine-1-carbonyl]-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5e) Yield: 168 mg (73%); white solid; mp 204–206 °C. 1H NMR (400 MHz, CDCl3): δ = 8.22 (ddd, J = 4.9, 1.9, 0.8 Hz, 1 H), 7.57–7.50 (m, 1 H), 7.42–7.33 (m, 1 H), 7.29–7.24 (m, 2 H), 6.75–6.66 (m, 2 H), 5.52 (s, 1 H), 4.44 (s, 1 H), 4.01–3.41 (m, 8 H), 2.60 (m, 2 H), 2.30–2.24 (m, 2 H), 2.12–2.06 (m, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.36, 167.27, 164.09, 158.70, 148.09, 137.89, 135.88, 134.66, 129.43, 115.84, 115.62, 114.57, 107.45, 77.06, 67.38, 54.51, 46.22, 44.95, 44.49, 43.98, 36.42, 23.69, 22.20. HRMS-ESI: m/z [M + H]+ calcd for C25H25O2N5Cl: 462.17025; found: 462.16913. 3-(4-Chlorophenyl)-2-(2,6-dimethylmorpholine-4-carbonyl)-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5f) Yield: 116 mg (56%); off-white solid; mp 200–202 °C. 1H NMR (400 MHz, CDCl3): δ = 7.37–7.27 (m, 2 H), 7.18 (dd, J = 36.9, 6.9 Hz, 2 H), 5.74 (s, 1 H), 4.34 (dd, J = 23.1, 13.8 Hz, 2 H), 3.81 (d, J = 12.8 Hz, 1 H), 3.67 (s, 2 H), 3.09–2.82 (m, 1 H), 2.59 (d, J = 27.8 Hz, 3 H), 2.26 (d, J = 6.3 Hz, 2 H), 2.13–2.01 (m, 2 H), 1.33–1.13 (m, 6 H). 13C NMR (101 MHz, CDCl3): δ = 192.33, 167.63, 163.92, 139.24, 134.97, 130.41, 129.07, 128.14, 126.26, 115.93, 115.21, 71.76, 71.12, 70.57, 67.35, 55.68, 53.83, 52.14, 51.79, 49.39, 48.95, 36.39, 23.65, 22.16, 18.65, 18.45. HRMS-ESI: m/z [M + H]+ calcd for C22H25O3N3Cl: 414.15821; found: 414.15790. 3-(4-Chlorophenyl)-4-oxo-2-(thiomorpholine-4-carbonyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5g) Yield: 118 mg (59%); white solid; mp 214–216 °C. 1H NMR (500 MHz, CDCl3): δ = 7.32 (td, J = 4.6, 3.0 Hz, 2 H), 7.28–7.25 (m, 1 H), 7.21–7.17 (m, 1 H), 5.42 (s, 1 H), 4.35 (s, 1 H), 4.31 (d, J = 11.7 Hz, 1 H), 4.02 (d, J = 10.2 Hz, 1 H), 3.80–3.71 (m, 1 H), 3.64–3.53 (m, 1 H), 2.96–2.85 (m, 1 H), 2.80–2.71 (m, 1 H), 2.61 (m, 4 H), 2.28 (dd, J = 9.5, 4.0 Hz, 2 H), 2.12–2.05 (m, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.37, 167.46, 164.06, 139.27, 135.07, 130.49, 129.12, 128.06, 126.27, 115.71, 67.36, 54.60, 48.96, 47.03, 36.40, 27.22, 26.65, 23.69, 22.17. HRMS-ESI: m/z [M + H]+ calcd for C20H21O2N3ClS: 402.10532; found: 402.10509. tert-Butyl 4-[3-(4-Chlorophenyl)-2-cyano-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonyl]piperazine-1-carboxylate (5h) Yield: 134 mg (55%); white solid; mp 118–120 °C. 1H NMR (500 MHz, CDCl3): δ = 7.37 (d, J = 8.4 Hz, 2 H), 7.24 (d, J = 8.4 Hz, 2 H), 5.45 (s, 1 H), 4.38 (s, 1 H), 3.96–3.25 (m, 8 H), 2.65–2.56 (m, 2 H), 2.29–2.24 (m, 2 H), 2.11–2.04 (m, 2 H), 1.48 (s, 9 H). 13C NMR (101 MHz, CDCl3): δ = 192.40, 167.21, 164.17, 154.36, 135.76, 134.70, 129.50, 115.84, 115.65, 80.92, 77.06, 67.29, 54.48, 46.36, 44.13, 36.41, 28.37, 23.68, 22.18. HRMS-ESI: m/z [M + H]+ calcd for C25H30O4N4Cl: 485.19561; found: 485.19501. 3-(4-Chlorophenyl)-4-oxo-2-(pyrrolidine-1-carbonyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5i) Yield: 98 mg (53%); off-white solid; mp 258–260 °C. 1H NMR (400 MHz, CDCl3): δ = 7.35 (d, J = 8.4 Hz, 2 H), 7.25 (d, J = 8.6 Hz, 2 H), 5.47 (s, 1 H), 4.47 (s, 1 H), 3.75–3.40 (m, 4 H), 2.60 (t, J = 5.6 Hz, 2 H), 2.37–2.21 (m, 2 H), 2.12–2.02 (m, 4 H), 1.96 (dd, J = 13.1, 5.7 Hz, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.58, 167.69, 162.77, 136.22, 134.39, 129.30, 115.41, 77.06, 67.97, 53.43, 48.51, 47.56, 36.43, 26.70, 23.65, 23.34, 22.22. HRMS-ESI: m/z [M + H]+ calcd for C20H21O2N3Cl: 370.13359; found: 370.13302. 3-(4-Fluorophenyl)-4-oxo-2-(piperidine-1-carbonyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5j) Yield: 98 mg (73%); white solid; mp 210–212 °C. 1H NMR (400 MHz, CDCl3): δ = 7.36–7.12 (m, 2 H), 7.14–6.90 (m, 2 H), 5.44 (s, 1 H), 4.40 (s, 1 H), 3.84–3.36 (m, 4 H), 2.67–2.46 (m, 2 H), 2.34–2.17 (m, 2 H), 2.09 (dd, J = 12.3, 6.1 Hz, 2 H), 1.86–1.58 (m, 6 H). 13C NMR (101 MHz, CDCl3): δ = 192.36, 167.35, 163.89, 163.58, 161.43, 133.46, 129.65, 116.18, 115.96, 115.76, 67.51, 54.19, 47.56, 45.47, 36.43, 25.34, 25.11, 24.04, 23.66, 22.19. HRMS-ESI: m/z [M + H]+ calcd for C20H21O2N3Cl: 354.17359; found: 354.17302 2-(2,6-Dimethylmorpholine-4-carbonyl)-3-(4-fluorophenyl)-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5k) Yield: 119 mg (60%); off-white solid; mp 150–152 °C. 1H NMR (500 MHz, CDCl3): δ = 7.26 (t, J = 10.3 Hz, 2 H), 7.08 (t, J = 8.4 Hz, 2 H), 5.49 (s, 1 H), 4.47–4.24 (m, 2 H), 4.06 (dd, J = 83.5, 21.9 Hz, 1 H), 3.82 (d, J = 12.4 Hz, 1 H), 3.64 (d, J = 31.2 Hz, 2 H), 2.58 (tt, J = 23.9, 11.8 Hz, 3 H), 2.29 (t, J = 19.2 Hz, 2 H), 2.15–2.00 (m, 2 H), 1.21 (dd, J = 47.3, 12.0 Hz, 6 H). 13C NMR (101 MHz, CDCl3): δ = 192.47, 167.16, 164.01, 163.66, 133.14, 129.71, 116.34, 116.12, 71.81, 71.09, 70.64, 67.43, 55.45, 53.72, 52.16, 49.43, 36.45, 23.71, 22.21, 18.67. HRMS-ESI: m/z [M + H]+ calcd for C22H25O3N3F: 398.18865; found: 398.18845. 3-(4-Fluorophenyl)-4-oxo-2-(4-phenylpiperazine-1-carbonyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5l) Yield: 153 mg (69%); white solid; mp 232–234 °C. 1H NMR (500 MHz, CDCl3): δ = 7.32–7.27 (m, 1 H), 7.12–7.07 (m, 1 H), 6.95 (dd, J = 7.7, 3.6 Hz, 1 H), 5.49 (s, 1 H), 4.47 (s, 1 H), 4.06–3.58 (m, 4 H), 3.48–2.89 (m, 4 H), 2.70–2.49 (m, 2 H), 2.42–2.19 (m, 2 H), 2.09 (t, J = 6.3 Hz, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.42, 167.18, 164.01, 161.54, 150.48, 133.24, 129.74, 129.37, 121.23, 117.05, 116.36, 116.14, 115.94, 67.49, 54.43, 49.41, 48.82, 46.54, 44.19, 36.45, 23.69, 22.21. HRMS-ESI: m/z [M + H]+ calcd for C26H26O2N4F: 445.20385; found: 445.20343. 3-(4-Fluorophenyl)-2-[4-(4-fluorophenyl)piperazine-1-carbonyl]-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5m) Yield: 173 mg (75%); white solid; mp 230–232 °C. 1H NMR (500 MHz, CDCl3): δ = 7.34–7.27 (m, 2 H), 7.12–7.05 (m, 2 H), 7.03–6.96 (m, 2 H), 6.93–6.84 (m, 2 H), 5.46 (s, 1 H), 4.46 (s, 1 H), 4.03 (d, J = 12.5 Hz, 1 H), 3.90–3.57 (m, 3 H), 3.35–2.99 (m, 4 H), 2.60 (m, 2 H), 2.31–2.24 (m, 2 H), 2.09 (t, J = 6.2 Hz, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.45, 167.07, 164.03, 161.57, 159.22, 156.82, 147.11, 133.20, 129.81, 129.72, 119.04, 116.39, 116.18, 116.00, 115.78, 67.45, 54.47, 50.42, 49.79, 46.60, 44.22, 36.47, 23.73, 22.23. HRMS-ESI: m/z [M + H]+ calcd for C26H25O2N4F2: 463.19430; found: 463.19401. 2-[4-(3-Chlorophenyl)piperazine-1-carbonyl]-3-(4-fluorophenyl)-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5n) Yield: 134 mg (64%); white solid; mp 248–250 °C. 1H NMR (500 MHz, CDCl3): δ = 7.32–7.28 (m, 2 H), 7.22–7.18 (m, 1 H), 7.12–7.07 (m, 2 H), 6.92–6.89 (m, 2 H), 6.82–6.78 (m, 1 H), 5.44 (s, 1 H), 4.45 (s, 1 H), 4.13–3.57 (m, 4 H), 3.24 (dd, J = 71.6, 62.7 Hz, 4 H), 2.65–2.57 (m, 2 H), 2.28 (m, 2 H), 2.12–2.07 (m, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.44, 167.13, 164.05, 161.56, 151.51, 135.17, 133.15, 130.30, 129.80, 129.72, 120.90, 116.89, 116.40, 116.18, 115.90, 115.84, 114.80, 77.06, 67.47, 54.42, 48.88, 48.30, 46.31, 43.99, 36.44, 23.70, 22.21. HRMS-ESI: m/z [M + H]+ calcd for C26H25O2N4ClF: 479.16507; found: 479.16446. 3-(4-Fluorophenyl)-2-[4-(4-methoxyphenyl)piperazine-1-carbonyl]-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5o) Yield: 166 mg (70%); off-white solid; mp 158–160 °C. 1H NMR (500 MHz, CDCl3): δ = 7.32–7.28 (m, 2 H), 7.11–7.06 (m, 2 H), 6.94–6.89 (m, 2 H), 6.87–6.83 (m, 2 H), 5.47 (s, 1 H), 4.46 (s, 1 H), 4.00 (d, J = 11.1 Hz, 1 H), 3.83 (s, 1 H), 3.78 (s, 3 H), 3.76–3.64 (m, 2 H), 3.27–2.97 (m, 4 H), 2.61 (q, J = 6.5 Hz, 2 H), 2.27 (dd, J = 11.3, 6.2 Hz, 2 H), 2.09 (m, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.45, 167.20, 163.97, 161.53, 154.85, 144.66, 133.23, 129.73, 119.34, 116.35, 116.01, 114.62, 77.07, 67.47, 55.58, 54.43, 50.87, 50.22, 46.72, 44.32, 36.45, 23.70, 22.21. HRMS-ESI: m/z [M + H]+ calcd for C27H28O3N4F: 475.21482; found: 475.21400. 3-(4-Fluorophenyl)-2-[4-(4-nitrophenyl)piperazine-1-carbonyl]-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5p) Yield: 176 mg (72%); yellow solid; mp 242–244 °C. 1H NMR (400 MHz, CDCl3): δ = 8.23–8.11 (m, 2 H), 7.33–7.28 (m, 2 H), 7.16–7.06 (m, 2 H), 6.93–6.83 (m, 2 H), 5.42 (s, 1 H), 4.45 (s, 1 H), 4.14 (d, J = 10.5 Hz, 1 H), 3.92 (s, 1 H), 3.70 (d, J = 44.9 Hz, 4 H), 3.49–3.31 (m, 2 H), 2.66–2.57 (m, 2 H), 2.32–2.24 (m, 2 H), 2.09 (m, 2 H). 13C NMR (101 MHz, CDCl3): δ = 189.94, 167.29, 162.04, 159.41, 152.98, 136.82, 132.53, 128.71, 124.29, 114.62, 114.19, 113.98, 111.69, 110.54, 66.89, 52.00, 44.51, 43.83, 41.95, 34.84, 21.86, 20.67. HRMS-ESI: m/z [M + H]+ calcd for C26H25O4N5F: 490.18927; found: 490.18851 3-(4-Fluorophenyl)-4-oxo-2-[4-(pyridin-2-yl)piperazine-1-carbonyl]-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5q) Yield: 162 mg (73%); off-white solid; mp 178–180 °C. 1H NMR (500 MHz, CDCl3): δ = 8.23–8.19 (m, 1 H), 7.57–7.50 (m, 1 H), 7.33–7.28 (m, 2 H), 7.09 (t, J = 8.5 Hz, 2 H), 6.75–6.65 (m, 2 H), 5.69 (s, 1 H), 4.47 (s, 1 H), 4.12–3.39 (m, 8 H), 2.83–2.47 (m, 2 H), 2.37–2.18 (m, 2 H), 2.08 (dd, J = 12.4, 6.2 Hz, 2 H). 13C NMR (101 MHz, CDCl3): δ = 192.44, 167.13, 164.05, 151.51, 135.17, 133.12, 130.30, 129.80, 120.90, 116.89, 116.40, 115.84, 114.80, 67.47, 54.42, 48.88, 48.30, 46.31, 43.99, 36.44, 23.70, 22.21. HRMS-ESI: m/z [M + H]+ calcd for C25H25O2N5F: 446.21482; found: 446.21400 2-(4-Ethylpiperazine-1-carbonyl)-3-(4-fluorophenyl)-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5r) Yield: 129 mg (65%); white solid; mp 142–144 °C. 1H NMR (500 MHz, CDCl3): δ = 7.29–7.25 (m, 1 H), 7.10–7.05 (m, 1 H), 5.54 (d, J = 3.8 Hz, 1 H), 4.42 (s, 1 H), 3.87 (d, J = 38.8 Hz, 1 H), 3.74–3.52 (m, 3 H), 2.69–2.55 (m, 4 H), 2.53–2.40 (m, 4 H), 2.29–2.24 (m, 2 H), 2.11–2.05 (m, 2 H), 1.11 (t, J = 7.2 Hz, 3 H). 13C NMR (101 MHz, CDCl3): δ = 192.42, 167.21, 163.76, 161.50, 133.28, 129.79, 116.29, 116.07, 115.90, 67.42, 54.36, 52.09, 51.51, 46.63, 44.21, 36.45, 23.69, 22.20, 11.93. HRMS-ESI: m/z [M + H]+ calcd for C22H25N4O2F: 397.203979; found: 397.20519 3-(4-Methoxyphenyl)-4-oxo-2-(piperidine-1-carbonyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5s) Yield: 117 mg (62%); white solid; mp 132–134 °C. 1H NMR (500 MHz, CDCl3): δ = 7.24–7.19 (m, 2 H), 6.93–6.87 (m, 2 H), 5.47 (s, 1 H), 4.38 (s, 1 H). 3.79 (s, 3 H), 3.78–3.71 (m, 1 H), 3.63 (d, J = 14.8 Hz, 1 H), 3.58–3.44 (m, 2 H), 2.59 (t, J = 8.0 Hz, 2 H), 2.28–2.23 (m, 2 H), 2.07 (dt, J = 11.9, 5.9 Hz, 2 H), 1.73 (s, 6 H). 13C NMR (126 MHz, CDCl3): δ = 192.51, 167.05, 163.88, 159.63, 129.60, 129.10, 116.15, 114.47, 77.06, 67.76, 55.23, 54.39, 47.61, 45.44, 36.51, 25.38, 25.14, 24.11, 23.73, 22.25. HRMS-ESI: m/z [M + H]+ calcd for C22H26N3O3: 380.19720; found: 380.19687. 4-Oxo-2-(piperidine-1-carbonyl)-3-(3,4,5-trimethoxyphenyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5t) Yield: 128 mg (58%); white solid; mp 198–200 °C. 1H NMR (400 MHz, CDCl3): δ = 6.53 (s, 2 H), 5.49 (s, 1 H), 4.34 (s, 1 H), 3.85 (d, J = 6.1 Hz, 9 H), 3.71–3.52 (m, 4 H), 2.66–2.54 (m, 2 H), 2.33–2.17 (m, 2 H), 2.12–2.06 (m, 2 H), 1.82–1.61 (m, 6 H). 13C NMR (101 MHz, CDCl3): δ = 192.47, 167.11, 163.82, 153.53, 138.34, 133.09, 115.96, 105.39, 67.63, 60.86, 56.27, 55.40, 47.59, 45.42, 36.54, 25.35, 24.09, 23.76, 22.30. HRMS-ESI: m/z [M + H]+ calcd for C22H26N3O3: 440.218000; found: 440.21798. 4-Oxo-3-phenyl-2-(piperidine-1-carbonyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5u) Yield: 115 mg (66%); white solid; mp 204–206 °C. 1H NMR (500 MHz, CDCl3): δ = 7.38 (ddd, J = 7.5, 4.4, 1.3 Hz, 2 H), 7.34–7.29 (m, 3 H), 5.44 (s, 1 H), 4.41 (s, 1 H), 3.80–3.71 (m, 1 H), 3.67–3.44 (m, 3 H), 2.60 (dd, J = 11.5, 5.7 Hz, 2 H), 2.29–2.23 (m, 2 H), 2.12–2.05 (m, 2 H), 1.62 (dt, J = 16.2, 7.7 Hz, 6 H). 13C NMR (101 MHz, CDCl3): δ = 192.40, 167.30, 163.77, 137.55, 129.07, 128.63, 127.94, 116.01, 77.06, 67.61, 54.93, 47.59, 45.45, 36.47, 25.36, 25.11, 24.07, 23.69, 22.21. HRMS-ESI: m/z [M + H]+ calcd for C21H24N3O2: 350.18630; found: 350.18632. 4-Oxo-2-(piperidine-1-carbonyl)-3-(o-tolyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5v) Yield: 116 mg (64%); white solid; mp 162–164 °C. 1H NMR (500 MHz, CDCl3): δ = 7.43 (d, J = 7.5 Hz, 1 H), 7.24–7.14 (m, 3 H), 5.48 (s, 1 H), 4.67 (s, 1 H), 3.98 (s, 1 H), 3.44 (dd, J = 105.7, 41.0 Hz, 3 H), 2.58 (s, 3 H), 2.57–2.53 (m, 2 H), 2.21 (dt, J = 8.2, 4.6 Hz, 2 H), 2.03 (dd, J = 11.4, 5.2 Hz, 2 H), 1.68 (d, J = 21.4 Hz, 6 H). 13C NMR (101 MHz, CDCl3): δ = 192.31, 166.43, 164.05, 136.46, 135.59, 130.62, 128.19, 127.93, 126.78, 118.52, 116.44, 67.69, 50.22, 47.54, 45.61, 36.48, 25.31, 24.12, 23.74, 22.05, 19.72. HRMS-ESI: m/z [M + H]+ calcd for C22H26N3O2: 364.20351; found: 364.20195. 3-(4-Nitrophenyl)-4-oxo-2-(piperidine-1-carbonyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5w) Yield: 106 mg (54%); white solid; mp 170–172 °C. 1H NMR (400 MHz, CDCl3): δ = 8.29–8.22 (m, 2 H), 7.52–7.47 (m, 2 H), 5.57 (s, 1 H), 4.51 (s, 1 H), 3.82 (d, J = 13.0 Hz, 1 H), 3.51 (dt, J = 18.0, 12.1 Hz, 3 H), 2.63 (dd, J = 10.2, 5.5 Hz, 2 H), 2.27 (dd, J = 14.7, 6.9 Hz, 2 H), 2.10 (dd, J = 12.3, 6.1 Hz, 2 H), 1.62 (s, 6 H). 13C NMR (126 MHz, CDCl3): δ = 192.32, 167.84, 163.03, 147.97, 144.88, 129.16, 124.42, 115.61, 115.53, 66.87, 54.45, 47.63, 45.67, 36.34, 25.35, 25.15, 24.02, 23.73, 22.17. HRMS-ESI: m/z [M + H]+ calcd for C21H22N4O4: 394.16420; found: 394.16340. 3-(4-Fluorophenyl)-6,6-dimethyl-4-oxo-2-(piperidine-1-carbonyl)-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5x) Yield: 142mg (72%); white solid; mp 160–162 °C. 1H NMR (500 MHz, CDCl3): δ = 7.29 (ddd, J = 7.0, 4.5, 2.0 Hz, 2 H), 7.10–7.05 (m, 2 H), 5.35 (s, 1 H). 4.40 (s, 1 H), 3.79 (d, J = 13.2 Hz, 1 H), 3.61 (d, J = 13.4 Hz, 1 H), 3.47 (dd, J = 23.6, 14.8 Hz, 2 H), 2.44 (d, J = 5.8 Hz, 2 H), 2.14 (dd, J = 40.0, 16.4 Hz, 2 H), 1.73 (d, J = 4.7 Hz, 6 H), 1.10 (d, J = 2.3 Hz, 6 H).13C NMR (101 MHz, CDCl3): δ = 191.83, 166.33, 163.92, 163.61, 161.46, 133.53, 129.64, 116.26, 116.05, 115.95, 114.47, 67.67, 54.11, 50.57, 47.60, 45.51, 37.42, 34.65, 29.07, 28.28, 25.37, 25.10, 24.06. HRMS-ESI: m/z [M + H]+ calcd for C23H27O2N3F: 396.20818; found: 396.20904. 3-(4-Fluorophenyl)-6,6-dimethyl-4-oxo-2-[4-(pyridin-2-yl)piperazine-1-carbonyl]-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5y) Yield: 172 mg (73%); white solid; mp 164–166 °C. 1H NMR (500 MHz, CDCl3): δ = 8.23–8.19 (m, 1 H), 7.53 (ddd, J = 8.9, 7.2, 2.0 Hz, 1 H), 7.34–7.29 (m, 2 H), 7.13–7.07 (m, 2 H), 6.74–6.70 (m, 1 H), 6.68 (d, J = 8.6 Hz, 1 H), 5.41 (s, 1 H), 4.45 (s, 1 H), 3.98 (d, J = 12.9 Hz, 1 H), 3.84 (t, J = 9.0 Hz, 3 H), 3.75–3.55 (m, 3 H), 3.50–3.40 (m, 1 H), 2.46 (s, 2 H), 2.18–2.09 (m, 2 H), 1.11 (d, J = 4.3 Hz, 6 H). 13C NMR (101 MHz, CDCl3): δ = 191.79, 165.99, 164.21, 158.72, 148.08, 137.91, 133.24, 129.79, 116.42, 116.21, 115.92, 114.57, 107.46, 67.68, 54.35, 50.62, 46.23, 44.98, 44.50, 43.99, 37.46, 34.70, 28.97, 28.38. HRMS-ESI: m/z [M + H]+ calcd for C27H29O2N5F: 474.23108; found: 474.22998. 3-(4-Fluorophenyl)-4-oxo-6-phenyl-2-[4-(pyridin-2-yl)piperazine-1-carbonyl]-2,3,4,5,6,7-hexahydro-1H-indole-2-carbonitrile (5z) Yield: 164 mg (63%); white solid; mp 210–212 °C. 1H NMR (500 MHz, CDCl3): δ = 8.29–8.13 (m, 1 H), 7.60–7.48 (m, 1 H), 7.39–7.31 (m, 2 H), 7.25 (m, 5 H), 7.10 (m, 2 H), 6.72 (dd, J = 7.1, 4.9 Hz, 1 H), 6.69 (d, J = 8.5 Hz, 1 H), 5.58 (d, J = 15.4 Hz, 1 H), 4.50 (d, J = 7.9 Hz, 1 H), 3.98 (d, J = 12.5 Hz, 1 H), 3.80 (t, J = 18.3 Hz, 3 H), 3.76–3.56 (m, 3 H), 3.53–3.40 (m, 2 H), 2.90–2.79 (m, 2 H), 2.57–2.54 (m, 2 H).13C NMR (101 MHz, CDCl3): δ = 191.03, 164.08, 158.68, 148.03, 142.26, 137.85, 129.84, 128.81, 127.18, 126.83, 126.72, 116.29, 116.08, 115.76, 114.52, 107.44, 77.06, 67.66, 54.36, 46.20, 44.94, 44.47, 43.93, 43.51, 41.07, 40.22, 31.28, 30.89. HRMS-ESI: m/z [M + H]+ calcd for C31H29O2N5F: 522.23097; found: 522.22998. 3-(4-Chlorophenyl)-2-cyano-N,N-diethyl-4-oxo-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxamide (5a′) Yield: 190 mg (52%); colorless liquid. 1H NMR (400 MHz, CDCl3): δ = 7.34–7.30 (m, 2 H), 7.27 (d, J = 2.6 Hz, 1 H), 7.23–7.19 (m, 1 H), 5.69 (s, 1 H), 4.38–4.35 (m, 1 H), 3.54 (dt, J = 13.5, 6.8 Hz, 1 H), 3.50–3.37 (m, 3 H), 2.59 (dd, J = 12.4, 6.2 Hz, 2 H), 2.28 (dd, J = 6.9, 4.7 Hz, 2 H), 2.08 (dt, J = 12.6, 6.2 Hz, 2 H), 1.33 (t, J = 6.9 Hz, 3 H), 1.19 (t, J = 7.1 Hz, 3 H). 13C NMR (126 MHz, CDCl3): δ = 192.33, 167.80, 164.26, 139.64, 134.89, 130.33, 128.91, 128.06, 126.25, 115.81, 115.20, 67.54, 54.56, 42.27, 41.64, 36.41, 23.65, 22.17, 12.82, 12.40. HRMS-ESI: m/z [M + H]+ calcd for C20H23N3O2Cl: 372.14882; found: 372.14956. 1-[4-(4-Fluorophenyl)piperazin-1-yl]ethan-1-one (7) 1H NMR (400 MHz, CDCl3): δ = 7.02–6.94 (m, 2 H), 6.92–6.83 (m, 2 H), 3.81–3.73 (m, 2 H), 3.67–3.57 (m, 2 H), 3.13–2.97 (m, 4 H), 2.14 (s, 3 H). 13C NMR (101 MHz, CDCl3): δ = 169.05, 158.73, 156.35, 147.52, 118.59, 115.85, 115.53, 50.68, 50.32, 46.22, 41.35, 29.64, 21.30. HRMS-ESI: m/z [M + H]+ calcd for C12H16ON2F: 223.12412; found: 223.12470. Crystal Data for 5a C24H22N3O2Cl1, M = 401.88, monoclinic, space group P21 /n (No.14), a =14.005(12)Å, b = 14.440(12)Å, c = 10.998(9)Å, α = 90°, β = 112.583(18)°, γ = 90°, V = 2054(3)Å3, Z = 4, D c = 1.300 g/cm3, F 000 = 848, Bruker D8 QUEST PHOTON-100, Mo Kα radiation, λ = 0.71073 Å, T = 293(2) K, 2θmax = 50°, μ = 0.212 mm–1, 13591 reflections collected, 3595 unique (R int = 0.0667), 265 parameters, R1 = 0.0618, wR2 = 0.1542, R indices based on 2598 reflections with I > 2σ(I) (refinement on F 2), final GooF = 1.025, largest difference hole and peak = –0.390 and 0.570 e Å–3 (Figure 1). CCDC 2065225 contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures